Where does the Clinical Relevance information come from ?

Information is essentially from Damoiseaux et al. 2019 (Ann Rheum Dis. 78:879-89) with updates and references cited as they become available.

What is the difference between Clinical Relevance first and second level information ?

The first level should contain information on relevant follow-up testing in the respective clinical context, the recommended follow-up tests should be commercially available, and detailed test characteristics should not be given because of potential geographic and jurisdictional differences. Information based on case reports or small patient cohorts, as well as information on possible follow-up testing that is only available in specialized research laboratories, should only be provided in the second level information. Thus, first level information is extracted from the three main tables (Ann Rheum Dis. 78:879-89) while second level information is extracted from the three supplemental tables.

List of abbreviations: Ago, argonaute protein; AIH, autoimmune hepatitis; AIM, autoimmune myopathy; ALBIA, addressable laser-bead immuno-assay; AMA, antimitochondrial antibodies; APS, antiphospholipid syndrome; CENP, centromere-associated protein; Cep, centrosomal protein; CLIP, class II-associated invariant chain peptide; DCA, dividing cell antigen; DFS, dense fine speckled; DM, dermatomyositis; dsDNA, double stranded DNA; EBV, Epstein-Barr virus; EEA, early endosome antigen; ELISA, enzyme‐linked immunosorbent assay; ENA, extractable nuclear antigens; GPA, granulomatosis with polyangiitis; GRASP, glutamate receptor interacting protein-associated protein; GW, glycine (G) – tryptophan (W) repeat; HCV, hepatitis C virus; Hedls, human enhancer of decapping large subunit; HIV, human immunodeficiency virus; hUBF, human upstream binding factor; IIFA, indirect immunofluorescence assay; INCENP, inner centromere protein; KIF, kinesin family; LAP, lamin-associated polypeptide; LBPA, lysobiphosphatidic acid; LBR, lamin B receptor; LEDGF, lens epithelial derived growth factor; MCA, mitotic chromosomal antigen; MCTD, mixed connective tissue disease; MKLP, mitotic kinesin-like protein; MPP, M-phase phosphoprotein; MSA, mitotic spindle apparatus; NMP, nuclear matrix protein; NOR, nucleolus organizer region; NuMA, nuclear mitotic apparatus; NXP, nuclear matrix protein; PBC, primary biliary cholangitis; PCM, pericentriolar material; PCNA, proliferating cell nuclear antigen; PML, promyelocytic leukaemia; PM/Scl, polymyositis-scleroderma; RA, rheumatoid arthritis; RibP, ribosomal phosphoprotein; RNApol, RNA polymerase; RNP, ribonucleoprotein; SARD, systemic autoimmune rheumatic diseases; SjS, Sjögren’s syndrome; SLE, systemic lupus erythematosus; SMN, survival of motor neuron; SRP, signal recognition protein; ssDNA, single stranded deoxyribonucleic acid; SSc, systemic sclerosis; TIF, transcription intermediary factor; Tpr, translocated promoter region; TRIM, tripartite motif; tRNA, transfer ribonucleic acid; UCTD, undifferentiated connective tissue disease.